Coccidioidomycosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
m Changes made per Mahshid's request |
Category |
||
| Line 15: | Line 15: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}}[[Category:Emergency medicine]] | ||
[[Category:Disease]] | |||
[[Category:Primary care]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Pulmonology]] | |||
Revision as of 01:19, 21 September 2017
|
Coccidioidomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coccidioidomycosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Coccidioidomycosis cost-effectiveness of therapy |
|
Coccidioidomycosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Coccidioidomycosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective.[1]
References
- ↑ Stockamp NW, Thompson GR (2016). "Coccidioidomycosis". Infect. Dis. Clin. North Am. 30 (1): 229–46. doi:10.1016/j.idc.2015.10.008. PMID 26739609.